Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy

International Journal of Cardiovascular Imaging

Volumn 32, Issue 9, 2016, Pages 1403-1413

  Bennani Smires, Youssef ^a   Victor, Gérard ^b   Ribes, David ^a   Berry, Matthieu ^a,b   Cognet, Thomas ^a,b   Méjean, Simon ^a,b,c   Huart, Antoine ^a   Roussel, Murielle ^d   Petermann, Antoine ^a   Roncalli, Jérôme ^a,c   Carrié, Didier ^a,b,c   Rousseau, Hervé ^a,c   Berry, Isabelle ^b,c   Chauveau, Dominique ^a,c   Galinier, Michel ^a,b,c   Lairez, Olivier ^a,b,c  

^a CHU RANGUEIL   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d IUCT Oncopole ^*  (France)

Author keywords

Amyloid cardiomyopathy; Cardiac amyloidosis; Cardiac imaging; Heart failure with preserved ejection fraction

Indexed keywords

3,3 DIPHOSPHONO 1,2 PROPANODICARBOXYLIC ACID TC 99M; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CONTRAST MEDIUM;

AGED; AMYLOID CARDIOMYOPATHY; ARTICLE; CAMERA; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ECHOCARDIOGRAPH; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART AMYLOIDOSIS; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEART SCINTISCANNING; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PHENOTYPE; PILOT STUDY; PREVALENCE; QRS INTERVAL; SYSTOLIC BLOOD PRESSURE; AGE; AMYLOIDOSIS; CARDIOMYOPATHIES; DIAGNOSTIC IMAGING; FRANCE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE; HYPERTROPHY, LEFT VENTRICULAR; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; SCINTISCANNING; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; CARDIOMYOPATHIES; CONTRAST MEDIA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FRANCE; HEART FAILURE; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; PHENOTYPE; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 84973137988     PISSN: 15695794     EISSN: 15730743     Source Type: Journal    
DOI: 10.1007/s10554-016-0915-z     Document Type: Article

References (27)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251–259
2. Maurer MS, King DL, El-Khoury Rumbarger L, Packer M, Burkhoff D (2005) Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail 11(3):177–187
3. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol Heart Fail 2(2):113–122
4. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468(7320):93–97
5. Di Bella G, Pizzino F, Minutoli F, Zito C, Donato R, Dattilo G, Oreto G, Baldari S, Vita G, Khandheria BK, Carerj S (2014) The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease. Eur Heart J Cardiovasc Imaging 15(12):1307–1315
6. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14(8):803–869
7. Carroll JD, Gaasch WH, McAdam KP (1982) Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 49(1):9–13
8. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, Morehead A, Kitzman D, Oh J, Quinones M, Schiller NB, Stein JH, Weissman NJ (2004) American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 17(10):1086–1119
9. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18(12):1440–1463
10. Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R, Schulz-Menger J (2009) Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 53(3):284–291
11. Mekinian A, Lions C, Leleu X, Duhamel A, Lamblin N, Coiteux V, De Groote P, Hatron PY, Facon T, Beregi JP, Hachulla E, Launay D (2010) Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging. Am J Med 123(9):864–868
12. Austin BA, Tang WH, Rodriguez ER, Tan C, Flamm SD, Taylor DO, Starling RC, Desai MY (2009) Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. J Am Coll Cardiol Cardiovasc Imaging 2(12):1369–1377
13. Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, Salvi F, Gallo P, Gagliardi C, Branzi A (2011) Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 38(3):470–478
14. Toor AA, Ramdane BA, Joseph J, Thomas M, O’Hara C, Barlogie B, Walker P, Joseph L (2006) Cardiac nonamyloidotic immunoglobulin deposition disease. Mod Pathol 19(2):233–237
15. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36(38):2585–2594
16. Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, Lane T, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD (2014) Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging 15(11):1289–1298
17. Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ (2014) CMR-based differentiation of AL and ATTR cardiac amyloidosis. J Am Coll Cardiol Cardiovasc Imaging 7(2):133–142
18. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M (2010) Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. J Am Coll Cardiol Cardiovasc Imaging 3(2):155–164
19. Ferrari R, Bohm M, Cleland JG, Paulus WJ, Pieske B, Rapezzi C, Tavazzi L (2015) Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail 17(7):665–671
20. Kyle RA, Greipp PR, O’Fallon WM (1986) Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood 68(1):220–224
21. Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ (2013) Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2(2):e000098
22. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo RC (2015) Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131(3):269–279
23. Borlaug BA, Redfield MM (2011) Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 123(18):2006–2013 (discussion 2014)
24. Gertz MA, Dispenzieri A, Sher T (2015) Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol 12(2):91–102
25. Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, de Fougerolles T, Maraganore J (2010) A status report on RNAi therapeutics. Silence 1(1):14
26. Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP (2012) Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 19(Suppl 1):43–44
27. Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H, Dierckx RA, Slart RH, Hazenberg BP (2014) Bone scintigraphy with (99 m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid 21(1):35–44